MedTrace Logo

Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients

NCT00716950 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2008-07-17

No results posted yet for this study

Summary

Hypertensive patients with moderate hypertension have a risk to develop cardiovascular events of 15-20% over a period of 10 years. It is important to reach quickly the advised target, but often this result can be obtained with a combination therapy. Some evidences demonstrate sartans and calcium channels blockers can be very useful and safe, but it is also important to verify which association can give side effects or give some pharmacokinetic interactions that can negatively influence the clinical combination efficacy.

Conditions

  • Essential Hypertension

Interventions

DRUG

valsartan/amlodpine

tablets; 160mg/5mg; od; 4 weeks

DRUG

losartan/amlodpine

tablets; 100mg/5mg; od; 4 weeks

Sponsors & Collaborators

  • University of Pavia

    lead OTHER

Principal Investigators

  • Roberto Fogari, MD · University of Pavia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00716950 on ClinicalTrials.gov